$ANIX
Anixa Biosciences Inc

2025 Q1 Form 10-K Financial Statement

#000149315225001787 Filed on January 10, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4 2024
Revenue $210.0K
YoY Change 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $6.396M
YoY Change 34.12%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.396M
YoY Change 34.12%
Operating Profit -$13.83M
YoY Change 25.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$12.55M
YoY Change 27.96%
Net Earnings / Revenue -5978.1%
Basic Earnings Per Share -$0.39
Diluted Earnings Per Share -$0.39
COMMON SHARES
Basic Shares Outstanding 32.20M shares 31.90K shares
Diluted Shares Outstanding 31.90K shares

Balance Sheet

Concept 2025 Q1 2024 Q4 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.271M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.36M
YoY Change -15.75%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $229.0K
YoY Change 37.95%
TOTAL ASSETS
Total Short-Term Assets $21.36M
Total Long-Term Assets $229.0K
Total Assets $21.59M
YoY Change -15.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $525.0K
YoY Change 154.85%
Accrued Expenses $1.946M
YoY Change 9.94%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.500M
YoY Change 23.27%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.500M
Total Long-Term Liabilities
Total Liabilities $2.703M
YoY Change 25.66%
SHAREHOLDERS EQUITY
Retained Earnings -$240.8M
YoY Change 5.5%
Common Stock $322.0K
YoY Change 3.54%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.000K
YoY Change
Treasury Stock Shares
Shareholders Equity $20.00M
YoY Change
Total Liabilities & Shareholders Equity $21.59M
YoY Change -15.4%

Cashflow Statement

Concept 2025 Q1 2024 Q4 2024
OPERATING ACTIVITIES
Net Income -$12.55M
YoY Change 27.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$7.335M
YoY Change 18.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $4.276M
YoY Change -176.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$2.949M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $3.415M
YoY Change 833.06%
NET CHANGE
Cash From Operating Activities -$7.335M
Cash From Investing Activities $4.276M
Cash From Financing Activities $3.415M
Net Change In Cash $356.0K
YoY Change -103.11%
FREE CASH FLOW
Cash From Operating Activities -$7.335M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0000715446
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
usd
CY2024 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024 us-gaap Royalty Expense
RoyaltyExpense
usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2023 ANIX Non Cash Investing Activity Modification To Operating Lease Rightofuse Asset
NonCashInvestingActivityModificationToOperatingLeaseRightofuseAsset
usd
CY2023 ANIX Non Cash Financing Activity Operating Lease Liability
NonCashFinancingActivityOperatingLeaseLiability
usd
CY2024 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2024 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
270000 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1265000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1242000 usd
CY2024 dei Entity File Number
EntityFileNumber
001-37492
CY2024 dei Entity Registrant Name
EntityRegistrantName
ANIXA BIOSCIENCES, INC.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2622630
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
3150 Almaden Expressway
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95118
CY2024 dei City Area Code
CityAreaCode
(408)
CY2024 dei Local Phone Number
LocalPhoneNumber
708-9808
CY2024Q4 us-gaap Assets Current
AssetsCurrent
21362000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
25356000 usd
CY2024 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2024 dei Trading Symbol
TradingSymbol
ANIX
CY2024 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Public Float
EntityPublicFloat
90560860 usd
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32196862 shares
CY2024 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.01
CY2024 ANIX No Insider Trading Flag
NoInsiderTradingFlag
true
CY2024 dei Auditor Firm
AuditorFirmId
200
CY2024 dei Auditor Name
AuditorName
HASKELL & WHITE LLP
CY2024 dei Auditor Location
AuditorLocation
Irvine, California
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1271000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
915000 usd
CY2024Q4 us-gaap Short Term Investments
ShortTermInvestments
18653000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
22929000 usd
CY2024Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
173000 usd
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
229000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166000 usd
CY2024Q4 us-gaap Assets
Assets
21591000 usd
CY2023Q4 us-gaap Assets
Assets
25522000 usd
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
525000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
206000 usd
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1770000 usd
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52000 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2500000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
203000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
123000 usd
CY2024Q4 us-gaap Liabilities
Liabilities
2703000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2151000 usd
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
100
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
100
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
19860 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
19860 shares
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32196862 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32196862 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31145219 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31145219 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
322000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
311000 usd
CY2024Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
260432000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
252222000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240750000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228196000 usd
CY2024Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2000 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2000 shares
CY2024Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
19998000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24337000 usd
CY2024Q4 us-gaap Minority Interest
MinorityInterest
-1110000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23371000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-966000 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18888000 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21591000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25522000 usd
CY2023 us-gaap Royalty Expense
RoyaltyExpense
161000 usd
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6396000 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4769000 usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
210000 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7435000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6291000 usd
CY2024 us-gaap Costs And Expenses
CostsAndExpenses
13831000 usd
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-13831000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-11011000 usd
CY2024 us-gaap Interest Income Other
InterestIncomeOther
1133000 usd
CY2023 us-gaap Interest Income Other
InterestIncomeOther
1081000 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-12698000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-9930000 usd
CY2024 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-144000 usd
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-119000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-12554000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-9811000 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31898 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31898 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30980 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30980 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28200000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4422000 usd
CY2023 ANIX Adjustments To Additional Paid In Capital Options Issued
AdjustmentsToAdditionalPaidInCapitalOptionsIssued
221000 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
353000 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
92000 usd
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-9930000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23371000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23371000 usd
CY2024 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4420000 usd
CY2024 ANIX Adjustments To Additional Paid In Capital Options Issued
AdjustmentsToAdditionalPaidInCapitalOptionsIssued
125000 usd
CY2024 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
456000 usd
CY2024 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
255000 usd
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
168000 usd
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2955000 usd
CY2024 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10000 usd
CY2024 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
6000 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-12698000 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18888000 usd
CY2024Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18888000 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-12698000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-9930000 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
4420000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
4422000 usd
CY2024 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
125000 usd
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
221000 usd
CY2024 ANIX Common Stock Issued To Consultants
CommonStockIssuedToConsultants
255000 usd
CY2023 ANIX Common Stock Issued To Consultants
CommonStockIssuedToConsultants
92000 usd
CY2024 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
37000 usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
46000 usd
CY2024 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-97000 usd
CY2023 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
224000 usd
CY2024 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
23000 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
775000 usd
CY2024 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
319000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-59000 usd
CY2024 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
176000 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
44000 usd
CY2024 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-43000 usd
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-46000 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7335000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6209000 usd
CY2024 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
63770000 usd
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
44411000 usd
CY2024 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
68046000 usd
CY2023 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
38809000 usd
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4276000 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5602000 usd
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2955000 usd
CY2024 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
10000 usd
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
13000 usd
CY2024 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
456000 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
353000 usd
CY2024 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
6000 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3415000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
366000 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
356000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11445000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
915000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12360000 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1271000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
915000 usd
CY2024 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
1230000 usd
CY2023 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
838000 usd
CY2024 ANIX Non Cash Investing Activity Modification To Operating Lease Rightofuse Asset
NonCashInvestingActivityModificationToOperatingLeaseRightofuseAsset
-100000 usd
CY2024 ANIX Non Cash Financing Activity Operating Lease Liability
NonCashFinancingActivityOperatingLeaseLiability
100000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-847000 usd
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-119000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-966000 usd
CY2024 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-144000 usd
CY2024Q4 us-gaap Minority Interest
MinorityInterest
-1110000 usd
CY2024 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
3.17
CY2024Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6000 usd
CY2024 ANIX Revenue Recognition Percentage
RevenueRecognitionPercentage
1 pure
CY2024Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
19823000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23707000 usd
CY2024Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
18653000 usd
CY2023Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
22929000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4843000 usd
CY2024 us-gaap Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1
NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1
P1Y8M12D
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.94
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.29
CY2024 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M15D
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y5M19D
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7648 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0027 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0387 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0387 pure
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_ziTbDdRlrLo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zopE1KY6LvSi">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are used for, but not limited to, determining stock-based compensation, asset impairment evaluations, tax assets and liabilities, license fee revenue, research and development expense accruals, the allowance for doubtful accounts, depreciation lives and other contingencies. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zahsGK0LY5a5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z8VyaQ0w0RCk">Concentration of Credit Risks</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject us to concentrations of credit risk are cash equivalents, short-term investments and accounts receivable. Cash equivalents are primarily highly rated money market funds. Short-term investments are U.S. treasury bills. Where applicable, management reviews our accounts receivable and other receivables for potential doubtful accounts and maintains an allowance for estimated uncollectible amounts. Our policy is to write-off uncollectable amounts at the time it is determined that collection will not occur. One licensee accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221101__20231031__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zBDoUDbpBmL7" title="Concentration risk, percentage">100</span>% of revenues from patent licensing activities during fiscal year 2023. We recorded no revenue in fiscal year 2024.</p>
CY2024Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1126000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1114000 usd
CY2024Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
626000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
626000 usd
CY2024Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
194000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000 usd
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1770000 usd
CY2024Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2000 shares
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
56000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
63000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
64000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
66000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
63000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
312000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
80000 usd
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
232000 usd
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29000 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
203000 usd
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
232000 usd
CY2024 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2284000000 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-739000000 usd
CY2024 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-754000000 usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-583000000 usd
CY2024 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
3038000000 usd
CY2023 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
1322000000 usd
CY2024Q4 ANIX Federal And State Nol And Tax Credit Carryforwards
FederalAndStateNOLAndTaxCreditCarryforwards
29198000000 usd
CY2023Q4 ANIX Federal And State Nol And Tax Credit Carryforwards
FederalAndStateNOLAndTaxCreditCarryforwards
26532000000 usd
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
8394000000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
7752000000 usd
CY2024Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
161000000 usd
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
218000000 usd
CY2024Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37753000000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34502000000 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37753000000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34502000000 usd
CY2024 ANIX Valuation Allowance Deferred Tax Asset Percentage
ValuationAllowanceDeferredTaxAssetPercentage
1 pure
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2024 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2667000 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2085000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2024 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-887000 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0699 pure
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-693000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0698 pure
CY2024 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
21000 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0017 pure
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
20000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0020 pure
CY2024 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
495000 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0390 pure
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1436000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.1446 pure
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3038000 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2392 pure
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1322000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.1332 pure
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2024Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0 usd
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 segment
CY2024 us-gaap Profit Loss
ProfitLoss
-12698000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-9930000 usd
CY2024 us-gaap Profit Loss
ProfitLoss
-12698000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-9930000 usd
CY2024 us-gaap Costs And Expenses
CostsAndExpenses
13831000 usd
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
11221000 usd
CY2024 ANIX Noncash Sharebased Compensation
NoncashSharebasedCompensation
-4782000 usd
CY2023 ANIX Noncash Sharebased Compensation
NoncashSharebasedCompensation
-4735000 usd
CY2024 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9049000 usd
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
6486000 usd
CY2024 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9049000 usd
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
6486000 usd
CY2024Q4 us-gaap Assets
Assets
21591000 usd
CY2023Q4 us-gaap Assets
Assets
25522000 usd
CY2024Q4 us-gaap Assets
Assets
21591000 usd
CY2023Q4 us-gaap Assets
Assets
25522000 usd
CY2024 us-gaap Revenues
Revenues
210000 usd
CY2024 ANIX Royalty Expense And Licensing Expense
RoyaltyExpenseAndLicensingExpense
161000 usd
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
true
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
11221000 usd
CY2024 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9049000 usd
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
6486000 usd
CY2024 dei Amendment Flag
AmendmentFlag
false

Files In Submission

Name View Source Status
0001493152-25-001787-index-headers.html Edgar Link pending
0001493152-25-001787-index.html Edgar Link pending
0001493152-25-001787.txt Edgar Link pending
0001493152-25-001787-xbrl.zip Edgar Link pending
anix-20241031.xsd Edgar Link pending
anix-20241031_cal.xml Edgar Link unprocessable
anix-20241031_def.xml Edgar Link unprocessable
ex14.htm Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
anix-20241031_pre.xml Edgar Link unprocessable
anix-20241031_lab.xml Edgar Link unprocessable
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending